Vax-Action: tackling effectively vaccine hesitancy in Europe
- Funded by European Commission
- Total publications:0 publications
Grant number: 101133273
Grant search
Key facts
Disease
COVID-19, mpoxStart & end year
20232026Known Financial Commitments (USD)
$1,511,058.28Funder
European CommissionPrincipal Investigator
Correia TiagoResearch Location
Portugal, Italy…Lead Research Institution
UNIVERSIDADE NOVA DE LISBOAResearch Priority Alignment
N/A
Research Category
Policies for public health, disease control & community resilience
Research Subcategory
Community engagement
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)Unspecified
Vulnerable Population
Internally Displaced and MigrantsOther
Occupations of Interest
Health Personnel
Mpox Research Priorities
Policies for public health, disease control & community resilience
Mpox Research Sub Priorities
Risk communication & community engagement e.g. key populations
Abstract
Vaccine hesitancy is the delay in acceptance or refusal of vaccines despite their availability. It is not a new problem, but a problem increasingly being recognized globally, and poses an academic and political concern. Its main implication reflects in lower-than-expected vaccine uptake rates. Two main strategies to lessen vaccine hesitancy stand out: targeted at people at large (communication campaigns, fact-checking, etc.) and at frontline healthcare workers, FHW, (training, manuals, etc.). However, it is yet not clear what works well, for whom, when, and under which circumstances. VAX-ACTION aims to support EU Member States and relevant stakeholders to implement a combination of tailored, evidence-based interventions aimed to reduce vaccine hesitancy. It addresses the need to understand what type of interventions are now available, which are effective, how to translate effective interventions to new contexts, and to explain the unsuccessful ones to create opportunities for learning and redesign. VAX-ACTION key relevance is to design and implement interventions and recommendations built on sound theory, existing evidence, and best practices of principles in health evaluation. We use a co-design model to engage FHW, and targeted populations (i.e., newly arrived migrants, hesitant parents, people of low socio-economic status) to tailor interventions regarding recently approved vaccines such as Covid-19 and mpox, and long-standing vaccines in national vaccination programmes. Interventions will be conducted in target regions in Portugal, Italy, France, Romania, and Czechia. Interventions are designed and evaluated in two settings per target region (the intervention group and control group, 1:1). The recommendations for embedding improvement and change will be prioritised along with tailored dissemination and evaluation strategies. This will support scale up and translation to other member states, WHO European Region members and other countries.